039 Solriamfetol real world experience study (SURWEY): safety and effectiveness for patients with na...
039 Solriamfetol real world experience study (SURWEY): safety and effectiveness for patients with narcolepsy from Germany
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
IntroductionSolriamfetol is a dopamine/norepinephrine reuptake inhibitor approved in the EU for excessive daytime sleepiness (EDS) associated with narcolepsy. This real-world study characterises outcomes following solriamfetol initiation.MethodsSURWEY is an ongoing retrospective chart review (Germany, France, Italy). Patients (≥18 years old, EDS du...
Alternative Titles
Full title
039 Solriamfetol real world experience study (SURWEY): safety and effectiveness for patients with narcolepsy from Germany
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2708269084
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2708269084
Other Identifiers
ISSN
0022-3050
E-ISSN
1468-330X
DOI
10.1136/jnnp-2022-abn2.83
